Switch to:
Also traded in: Germany, Sweden, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
MVRBF's Cash-to-Debt is ranked higher than
86% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. MVRBF: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MVRBF' s Cash-to-Debt Range Over the Past 10 Years
Min: 10.06  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.90
MVRBF's Equity-to-Asset is ranked higher than
85% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. MVRBF: 0.90 )
Ranked among companies with meaningful Equity-to-Asset only.
MVRBF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.75  Med: 0.86 Max: 0.92
Current: 0.9
0.75
0.92
Piotroski F-Score: 4
Altman Z-Score: 8.12
WACC vs ROIC
7.98%
-48.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -57.59
MVRBF's Operating Margin % is ranked higher than
55% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. MVRBF: -57.59 )
Ranked among companies with meaningful Operating Margin % only.
MVRBF' s Operating Margin % Range Over the Past 10 Years
Min: -544.37  Med: -14.72 Max: 67.27
Current: -57.59
-544.37
67.27
Net Margin % -57.00
MVRBF's Net Margin % is ranked higher than
55% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. MVRBF: -57.00 )
Ranked among companies with meaningful Net Margin % only.
MVRBF' s Net Margin % Range Over the Past 10 Years
Min: -527.08  Med: -54.43 Max: 64.11
Current: -57
-527.08
64.11
ROE % -12.50
MVRBF's ROE % is ranked higher than
67% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. MVRBF: -12.50 )
Ranked among companies with meaningful ROE % only.
MVRBF' s ROE % Range Over the Past 10 Years
Min: -69.41  Med: -6.41 Max: 79.91
Current: -12.5
-69.41
79.91
ROA % -11.22
MVRBF's ROA % is ranked higher than
68% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. MVRBF: -11.22 )
Ranked among companies with meaningful ROA % only.
MVRBF' s ROA % Range Over the Past 10 Years
Min: -52.66  Med: -12.94 Max: 71.26
Current: -11.22
-52.66
71.26
ROC (Joel Greenblatt) % -681.63
MVRBF's ROC (Joel Greenblatt) % is ranked lower than
55% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. MVRBF: -681.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MVRBF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -518.61  Med: -18.65 Max: 1014.95
Current: -681.63
-518.61
1014.95
3-Year Revenue Growth Rate 60.20
MVRBF's 3-Year Revenue Growth Rate is ranked higher than
90% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. MVRBF: 60.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MVRBF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -47.1  Med: 4.1 Max: 85.9
Current: 60.2
-47.1
85.9
GuruFocus has detected 2 Warning Signs with Medivir AB $MVRBF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MVRBF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with MVRBF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412 
Compare:NAS:OCUL, OTCPK:CNBX, OTCPK:MDGEF, OTCPK:MXDHF, NAS:IDRA, OTCPK:RCAR, AMEX:MTNB, NAS:KMDA, OTCPK:CLVLF, OTCPK:PRMCF, NAS:CMRX, NAS:NERV, NAS:DVAX, NAS:CALA, NAS:EDGE, NAS:AVXL, NAS:SGMO, OTCPK:SIGA, NAS:VYGR, OTCPK:OXBDF » details
Traded in other countries:MVR.Germany, MVIR B.Sweden, 0GP7.UK,
Medivir AB is a research based pharmaceutical company with a focus on infectious diseases and oncology. It is engaged in the design of protease inhibitors and in the science of nucleotides and nucleosides.

Medivir AB is a pharmaceutical company with an R&D focus on infectious diseases and hepatitis C. The Company works with the entire development chain, from the early research to the finished pharmaceutical product on the market. Its research focuses on infectious diseases and has expertise in the chemistry and biology of the enzyme classes, polymerase and protease. The research portfolio comprises nine pharmaceutical projects, five of which are being conducted in collaboration with partners. Seven of the projects focus on the development of antiviral pharmaceuticals, of which four are conducted in the hepatitis C sphere. The protease inhibitor, simeprevir, has been developed by the Company and Janssen. Positive simeprevir phase III data was reported in December 2012 that will, together with previous phase II data, form the basis for registration applications in the USA, Europe and Japan. The Company markets pharmaceuticals in the Nordic market. The product range comprises approximately 16 prescription pharmaceuticals in different therapeutic spheres. The products include Citodon, Laxabon,Lithionit, Mollipect and Paraflex. Parallel imports of pharmaceuticals to the Swedish market are conducted via the wholly owned subsidiary company, Cross Pharma.

Ratios

vs
industry
vs
history
PB Ratio 1.42
MVRBF's PB Ratio is ranked higher than
83% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. MVRBF: 1.42 )
Ranked among companies with meaningful PB Ratio only.
MVRBF' s PB Ratio Range Over the Past 10 Years
Min: 0.91  Med: 2.07 Max: 14.46
Current: 1.42
0.91
14.46
PS Ratio 6.22
MVRBF's PS Ratio is ranked higher than
66% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. MVRBF: 6.22 )
Ranked among companies with meaningful PS Ratio only.
MVRBF' s PS Ratio Range Over the Past 10 Years
Min: 1.34  Med: 5.96 Max: 83.31
Current: 6.22
1.34
83.31
EV-to-EBIT -4.82
MVRBF's EV-to-EBIT is ranked lower than
99.99% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. MVRBF: -4.82 )
Ranked among companies with meaningful EV-to-EBIT only.
MVRBF' s EV-to-EBIT Range Over the Past 10 Years
Min: -72.1  Med: -7.8 Max: 127.8
Current: -4.82
-72.1
127.8
EV-to-EBITDA -4.82
MVRBF's EV-to-EBITDA is ranked lower than
99.99% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. MVRBF: -4.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
MVRBF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -72.1  Med: -7.8 Max: 127.8
Current: -4.82
-72.1
127.8
Current Ratio 9.95
MVRBF's Current Ratio is ranked higher than
80% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. MVRBF: 9.95 )
Ranked among companies with meaningful Current Ratio only.
MVRBF' s Current Ratio Range Over the Past 10 Years
Min: 1.84  Med: 4.54 Max: 11.67
Current: 9.95
1.84
11.67
Quick Ratio 9.69
MVRBF's Quick Ratio is ranked higher than
79% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. MVRBF: 9.69 )
Ranked among companies with meaningful Quick Ratio only.
MVRBF' s Quick Ratio Range Over the Past 10 Years
Min: 1.83  Med: 4.42 Max: 11.49
Current: 9.69
1.83
11.49
Days Inventory 93.66
MVRBF's Days Inventory is ranked higher than
65% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. MVRBF: 93.66 )
Ranked among companies with meaningful Days Inventory only.
MVRBF' s Days Inventory Range Over the Past 10 Years
Min: 49.91  Med: 119.94 Max: 480.13
Current: 93.66
49.91
480.13

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 5.00
MVRBF's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. MVRBF: 5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MVRBF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.1  Med: -9.6 Max: 5
Current: 5
-28.1
5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.32
MVRBF's Price-to-Net-Cash is ranked higher than
82% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. MVRBF: 2.32 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MVRBF' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.71  Med: 9.57 Max: 34.7
Current: 2.32
1.71
34.7
Price-to-Net-Current-Asset-Value 2.05
MVRBF's Price-to-Net-Current-Asset-Value is ranked higher than
84% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. MVRBF: 2.05 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MVRBF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.53  Med: 5.17 Max: 16.15
Current: 2.05
1.53
16.15
Price-to-Tangible-Book 2.00
MVRBF's Price-to-Tangible-Book is ranked higher than
78% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. MVRBF: 2.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MVRBF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.49  Med: 4.11 Max: 11.21
Current: 2
1.49
11.21
Price-to-Intrinsic-Value-Projected-FCF 0.51
MVRBF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
95% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.22 vs. MVRBF: 0.51 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MVRBF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.4  Med: 1.14 Max: 34.35
Current: 0.51
0.4
34.35
Price-to-Median-PS-Value 1.05
MVRBF's Price-to-Median-PS-Value is ranked lower than
55% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. MVRBF: 1.05 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MVRBF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1 Max: 13.67
Current: 1.05
0.23
13.67
Earnings Yield (Greenblatt) % -20.75
MVRBF's Earnings Yield (Greenblatt) % is ranked lower than
66% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. MVRBF: -20.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MVRBF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.8  Med: 12.3 Max: 95.1
Current: -20.75
0.8
95.1

More Statistics

Revenue (TTM) (Mil) $36.70
EPS (TTM) $ -0.76
Beta0.31
Short Percentage of Float0.00%
52-Week Range $7.40 - 10.10
Shares Outstanding (Mil)26.87
» More Articles for MVRBF

Headlines

Articles On GuruFocus.com
Johnson & Johnson's Janssen Pharmaceutical Starts Study on Hepatitis C Therapy Nov 28 2016 

More From Other Websites
Medivir Completes Transition of Commercial Products to Fully Focus on Research and Development Mar 16 2017
Presentation of the Result of Medivir's Voluntary Redemption Programme Mar 03 2017
Medivir's Nomination Committee Proposes new Board of Directors Ahead of 2017 AGM Feb 24 2017
Executive Management Team Members Increase Their Holdings in Medivir Feb 17 2017
Christine Lind new CEO of Medivir AB Effective 1 April 2017 Feb 09 2017
Medivir Capital Markets Meeting on 23 February 2017 Feb 06 2017
Resolutions at the Extraordinary General Meeting in Medivir on 2 February 2017 Feb 02 2017
Notice of Extraordinary General Meeting of Medivir AB (publ) Jan 10 2017
Medivir - Invitation to Conference Call and Webcast Jan 09 2017
Medivir Completes Previously Announced Oncology Programs Acquisition Dec 29 2016
Medivir Completes the Divestment of BioPhausia - a Transfer of Approx. SEK 870m to the Shareholders... Dec 15 2016
Medivir's fusion inhibitor for the treatment of Respiratory Syncytial Virus infection, MIV-323,... Dec 14 2016
MIV-711 Osteoarthritis Trial: Successful Third Independent Review of Safety Data and Trial Continues... Dec 08 2016
Medivir AB :MVRBY-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 Nov 28 2016
Medivir AB: Strong price momentum but will it sustain? Jun 16 2016
Medivir AB :MVRBY-US: Earnings Analysis: Q1, 2016 By the Numbers May 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)